MiNK Therapeutics Inc. (INKT)
INKT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | INKT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001840229 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Because the completion of anticipated funding is not entirely within the Company's control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q." | 10-Q 2026-11-12 |
| Cash and burn | $7.5M cash; operating cash flow -$1.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 5,133,645 (2026-11-06); 4,694,155 a year earlier; 34,519,540 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-01-28 | Source 2025-01-28 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $47K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $200K | -$2.6M | -$1.3M | $7.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$3.1M | -$2.1M | $8.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$2.7M | -$1.7M | $9.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$2.6M | -$2.1M | $13.4M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $0 | -$2.9M | -$941K | $9.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$4.2M | -$1.6M | $1.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$2.8M | -$1.3M | $3.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$2.5M | -$1.7M | $4.6M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-11-07 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 267 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.8% |
| 1 month | -8.7% |
| 3 months | -15.1% |
| Year to date | -16.2% |
| 1 year | -29.3% |
| From 52-week high | -34.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELOX | Eloxx Pharmaceuticals Inc. | $12.75 | -3.04% | $51.5M |
| GRML | Greenland Mines Ltd. | $3.50 | -3.05% | $51.9M |
| IMA | ImageneBio Inc. | $3.20 | -7.78% | $39.9M |
| TIL | Instil Bio Inc. | $5.75 | -5.43% | $39.0M |
| PMCB | PharmaCyte Biotech Inc. | $5.57 | -16.62% | $59.8M |
| CRBU | Caribou Biosciences Inc. | $0.3528 | -2.51% | $38.1M |
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier